

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
PTO FORM 1449**

Atty. Docket No.
1662/60903

Serial No.
10/649,399

Applicant(s)
Dolitzky et al.

Filing Date
August 26, 2003

Group
1624



U. S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE

* - If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
<i>[Signature]</i>	0 885 223 B1	Dec. 23, 1998	Europe				
<i>[Signature]</i>	WO 97/29108	Aug. 14, 1997	PCT				

* Copy of reference is not enclosed because reference is cited in Search Report (copy of reference provided by International Searching Authority).

OTHER DOCUMENTS

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
<i>[Signature]</i>	M. R. Hamden et al., Nucleosides & Nucleotides 9(4):499-513 (1990)
<i>[Signature]</i>	John Haleblan et al "Pharmaceutical Applications of Polymorphism"; Journal of Pharmaceutical Sciences, Vol. 58, No. 8, August 1969 - PP.911 - 929.
<i>[Signature]</i>	John K. Haleblan "Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications"; Journal of Pharmaceutical Sciences, Vol. 64, No. 8, August 1975 - PP1269 - 1288.
<i>[Signature]</i>	G. Michael Wall "Pharmaceutical Applications of Drug Crystal Studies", Pharmaceutical Manufacturing, Vol. 3, No.2, February 1986; PP 33-42.

EXAMINER

[Signature: Mun Bow]

DATE CONSIDERED

[Signature: 8/26/03]

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.